Cas:43120-28-1 methyl indazolyl-3-carboxylate manufacturer & supplier

Chemical Name:methyl indazolyl-3-carboxylate

CAS.NO:43120-28-1

Synonyms:Methyl 1H-indazole-3-carboxylate;1H-Indazole-3-carboxylic acid, methyl ester;Indazole-3-carboxylic Acid Methyl Ester;methyl indazole-3-carboxylate;1H-Indazole-3-Carboxylic Acid Methyl Ester;methyl indazolyl-3-carboxylate;methyl 3-indazolylcarboxylate;3-indazolecarboxylic acid methyl ester

Molecular Formula:C₉H₈N₂O₂

Molecular Weight:176.172

HS Code:2933990090

Physical and Chemical Properties:

Melting point:162-163ºC

Boiling point:345.2±15.0 °C at 760 mmHg

Density:1.3±0.1 g/cm3

Index of Refraction:1.648

PSA:54.98000

Exact Mass:176.058578

LogP:1.60

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like Methyl 1H-indazole-3-carboxylate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,3-indazolecarboxylic acid methyl ester physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Methyl 1H-indazole-3-carboxylate Use and application,methyl indazole-3-carboxylate technical grade,usp/ep/jp grade.

Related News: It does not require a production license for the drug substance, and can be produced in an ordinary chemical plant. As long as it reaches a certain level, it can be used for the synthesis of the drug substance. methyl indazolyl-3-carboxylate manufacturer It does not require a production license for the drug substance, and can be produced in an ordinary chemical plant. As long as it reaches a certain level, it can be used for the synthesis of the drug substance. methyl indazolyl-3-carboxylate supplier Oligomannate, which uses extract from marine brown algae as raw material, received a conditional green light to treat mild-to-moderate level AD, the National Medical Products Administration (NMPA) said in a statement on its website late on Saturday. methyl indazolyl-3-carboxylate vendor The GLOW trial doesn’t yet have the answer to that question, but Tendler pointed to encouraging early evidence from the regimen’s phase 2 trial, dubbed CAPTIVATE. Among eight patients who progressed after stopping the fixed-duration combo, six responded to subsequent Imbruvica monotherapy, while the other two didn’t have a response report, according to data presented at the recent American Society of Clinical Oncology annual meeting. methyl indazolyl-3-carboxylate factory Oligomannate, which uses extract from marine brown algae as raw material, received a conditional green light to treat mild-to-moderate level AD, the National Medical Products Administration (NMPA) said in a statement on its website late on Saturday.